



LKT Laboratories, Inc.

MK-0524

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID M4100

CAS No. 571170-77-9

Chemical Name

Synonym Laropiprant

Formula $C_{21}H_{19}ClFNO_4S$

Formula Wt. 435.90

Melting Point 178.6 °C


Purity ≥99%

Solubility Soluble in ethanol, DMSO, DMF, DMSO : PBS (pH 7.2) (1:1), and water (0.5 mg/ml at 25 °C)

Store Temp Ambient

Ship Temp Ambient

Description MK-0524 is a specific prostaglandin D2 receptor (DP1) inhibitor that functions as an inverse agonist. MK-0524 decreases niacin-induced flushing during niacin treatment of dyslipidemia and is most often studied in combination with niacin. The ability of MK-0524 to inhibit DP1 prevents PGD2-induced hyaluron synthesis, yielding beneficial results in preventing pathological changes associated with thyroid eye disease. This compound also has antithrombotic activity, displaying weak inhibitory action against the thromboxane A2 receptor, inhibiting platelet activation at high concentrations.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
M4100	1 mg	\$65.00
M4100	5 mg	\$125.00
M4100	25 mg	\$375.00

References Labrecque P, Roy SJ, Fréchette L, et al. Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS One. 2013 Jun 10;8(6):e65767. PMID: 23762421.

Philipose S, Konya V, Lazarevic M, et al. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One. 2012;7(8):e40222. PMID: 22870195.

Guo N, Bagloli CJ, O'Loughlin CW, et al. Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease. J Biol Chem. 2010 May 21;285(21):15794-804. PMID: 20308056.

Luo WL, Crumley T, Ebel D, et al. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTc interval in healthy volunteers. J Clin Pharmacol. 2010 Nov;50(11):1273-9. PMID: 20107202.

Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov;26(4):547-60. PMID: 19031552.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.